Blood Cell-Spheres: Growth, Description, and Potential

血细胞球：生长、描述和潜力

• 批准号: 8525088
• 负责人: Audrey Nadine Jajosky
• 金额: $ 3.92万
• 依托单位: WEST VIRGINIA UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-26 至 2014-07-25
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8525088
• 关键词: 3-Dimensional; Achievement; Animals; Antibodies; Biochemical; Blood; Blood Cells; Blood Coagulation Factor; Blood Platelets; Blood specimen; Bone Marrow; Cancer Etiology; Cell Line; Cells; Cellular Structures; Clinical Trials; Cytotoxic T-Lymphocytes; Decision Trees; Descriptor; Development; Electrons; Engineering; Environment; Generations; Genetic Variation; Goals; Growth; Growth Factor; Health; Hematopoietic Neoplasms; Hematopoietic stem cells; Image; Image Analysis; Imaging Techniques; Immune; Immunologics; Immunotherapy; In Vitro; Individual; Injury; Interleukin-6; Leukocytes; Life; Limb structure; Malignant - descriptor; Memory; Names; Natural Killer Cells; Natural regeneration; Normal Cell; Organ; Osteoblasts; Patients; Plasma; Pluripotent Stem Cells; Procedures; Research; Research Infrastructure; Resources; Sampling; Scanning; Scientist; Site; Specimen; Staining method; Stains; Stem Cell Research; Stem cells; Stromal Cells; Structure; Surface; Surface Antigens; Techniques; Thinking; Thrombin; Time; Tissues; Transplantation; Treatment Failure; Work; antibody engineering; blastema; cancer cell; cancer stem cell; cancer therapy; cell dedifferentiation; cell transformation; cell type; cytokine; design; human tissue; in vivo; insight; killings; leukemia; leukemic stem cell; light microscopy; macrophage; malignant breast neoplasm; mutant; optimism; progenitor; stem; theories; therapeutic target; tissue regeneration; tool; transdifferentiation; transmission process; two-photon

DESCRIPTION (provided by applicant): Goals and Strategy: This project seeks to develop individualized (patient-specific) therapies that will use antibodies and/or immune cells ("natural killer cells," macrophages, cytotoxic T cells) to attack cancer-causing leukemia "stem" cells (LSC's) without harming normal (blood) hematopoietic "stem" cells (HSC's). Lab activities are designed to (1) isolate and compare LSC's and normal HSC's from the same patient, (2) identify immunologic "targets" located only on the cancer-causing LSC's, and (3) explore immune-therapy options suggested by cell-structure differences. Imaging is vital and will include light microscopy, confocal (3-D), electron (transmission and scanning), and two-photon (3-D). When enhanced by staining techniques, cell micrographs can identify intracellular and surface structures as well as cell type and maturity level. Regarding growing, transforming, and analyzing cells, this proposal is essentially a logical extension of recent (and profound) stem-cell-related achievements. New insights and technical advances provide all the tools needed to develop immune-therapies: a useful conceptual framework, ways to transform cells, and high-tech lab and imaging resources. These advances inspired us to grow "blood cell-spheres" (BCS) using leukemia cells taken from routine patient blood specimens. These new leukemia BCS are exciting because other "cancer cell-spheres" are known to contain, concentrate, or "create" those critical cancer-causing "stem" cells that are rare and elusive inside a patient's body. Now, normal BCS will be grown (exciting since normal-cell spheres like "blastemas" also contain "stem" cells - these regenerate amputated limbs in animals). BCS will be imaged and analyzed to determine if (1) LSC's are inside leukemia BCS and (2) normal HSC's are inside normal BCS. If found - and stem cells have been found in similar cell-spheres - LSC's and normal HSC's will be compared using staining/imaging techniques that can show internal and surface details of spheres and the individual cells inside them. If the desired "stem" cells are not present, "newer generations" of BCS will be grown after adding more factors and cells that promote "stem" cell creation. When both normal and cancer "stem" cells can be isolated, they will be carefully compared to identify potential "targets" found only on LSC's. Finally, antibodies and/or immune cells that can attack these unique targets will be developed. Health-Impact: If LSC's and normal HSC's can be isolated from BCS grown from a leukemia patient's blood specimen, patient-specific immunotherapies can be developed. Individualized therapies would eliminate treatment failures caused by genetic variations and would represent one of the most ideal and unassuming strategies possible. Also, any lab procedure that enables scientists to derive "stem" or "progenitor" cells from more mature cells may help scientists regenerate human tissues and organs.

描述（由申请人提供）：目标和策略：该项目旨在开发个体化（患者特异性）疗法，该疗法将使用抗体和/或免疫细胞（“自然杀伤细胞”，巨噬细胞，细胞毒性T细胞）来攻击致癌白血病“干”细胞（LSC），而不损害正常（血液）造血“干”细胞（HSC）。实验室活动的目的是（1）分离和比较LSC和正常的HSC从同一个病人，（2）确定免疫“目标”只位于致癌LSC的，和（3）探索免疫治疗的选择建议细胞结构的差异。成像是至关重要的，将包括光学显微镜，共聚焦（3-D），电子（透射和扫描），和双光子（3-D）。当通过染色技术增强时，细胞显微照片可以识别细胞内和表面结构以及细胞类型和成熟水平。关于细胞的生长、转化和分析，这个提议基本上是最近（和深刻的）干细胞相关成就的逻辑延伸。新的见解和技术进步提供了开发免疫疗法所需的所有工具：有用的概念框架，转化细胞的方法以及高科技实验室和成像资源。这些进展启发我们使用从常规患者血液标本中提取的白血病细胞培养“血细胞球”（BCS）。这些新的白血病BCS令人兴奋，因为已知其他“癌细胞球”包含，浓缩或“创造”那些关键的致癌“干”细胞，这些细胞在患者体内是罕见和难以捉摸的。现在，正常的BCS将被培养出来（令人兴奋的是，像“胚基”这样的正常细胞球也包含“干”细胞--这些细胞可以再生动物的截肢）。将对BCS进行成像和分析，以确定（1）LSC是否在白血病BCS内，以及（2）正常HSC是否在正常BCS内。如果在相似的细胞球中发现了干细胞，将使用染色/成像技术比较LSC和正常HSC，这些技术可以显示球的内部和表面细节以及其中的单个细胞。如果所需的“干”细胞不存在，“新一代”的BCS将在添加更多促进“干”细胞产生的因子和细胞后生长。当正常和癌症“干”细胞都可以被分离出来时，它们将被仔细地比较，以确定仅在LSC上发现的潜在“目标”。最后，将开发可以攻击这些独特靶标的抗体和/或免疫细胞。健康影响：如果LSC和正常HSC可以从从白血病患者的血液标本中生长的BCS中分离出来，则可以开发患者特异性免疫疗法。个体化治疗将消除由遗传变异引起的治疗失败，并将代表最理想和最谦逊的策略之一。此外，任何使科学家能够从更成熟的细胞中获得“干”或“祖”细胞的实验室程序都可能有助于科学家再生人体组织和器官。